Mitochondria‐Associated Gene SLC25A32 as a Novel Prognostic and Immunotherapy Biomarker: From Pan‐Cancer Multiomics Analysis to Breast Cancer Validation
Analytical Cellular Pathology · 2024
DOI: 10.1155/2024/1373659 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Cellular Pathology, 2024. Verfasst von Shiqi Zuo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, Gu…. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, DNA Methylation, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Mutations in SLC25A32 in humans cause late‐onset exercise intolerance, which is associated with various neurological and metabolic diseases. However, its specific mechanism of action in tumour development is poorly understood owing to the lack of multiomics integrated analysis of SLC25A32 in pan‐cancer.
Methods
We used various analytical tools to comprehensively investigate the transcription, protein level, and promoter methylation of SLC25A32. Furthermore, the GSCA and cBioPortal databases were used to evaluate the inheritance impact and epigenetic alterations of SLC25A32 in pan‐cancer. SLC25A32 expression and the prognostic significance of copy number alterations in multiple cancers were compared using the UCSCXenaShiny and GEPIA2.0 platforms, and its specific function in breast cancer was experimentally verified.
Results
SLC25A32 is abnormally expressed at the transcriptional and protein levels in most cancer types, with aberrant DNA promoter methylation and significant gene amplification in most tumours. SLC25A32 is significantly associated with the survival prognosis of some cancers, immune infiltrating cells, tumour stemness, and immune‐related markers. SLC25A32 knockdown decreased breast tumour cell proliferation, invasion, and metastasis.
Conclusions
This study aimed to reveal SLC25A32 as a novel prognostic biomarker for pan‐cancer prediction and immunotherapy efficacy and specifically describes its underlying mechanism of action in breast cancer. SLC25A32 is widely differentially expressed in pan‐cancer with prognostic significance and is correlated with immune infiltration. Additionally, it can affect breast cancer occurrence and development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, Guangzhou, Guangdong 510315, China.
- Guangdong Provincial Key Laboratory of Molecular Tumor Pathology, Southern Medical University, Guangzhou 510515, Guangdong, China.
- Department of Pathology, School of Basic Medical Science, Southern Medical University, Guangzhou 510515, China.
- Department of Hepatology, Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, Guangzhou, Guangdong 510315, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zuo, S., He, S., Zhu, Z., Zhang, Y., Hou, Y., Wu, Z., & Tang, Y. (2024). Mitochondria‐Associated Gene SLC25A32 as a Novel Prognostic and Immunotherapy Biomarker: From Pan‐Cancer Multiomics Analysis to Breast Cancer Validation. Analytical Cellular Pathology. https://doi.org/10.1155/2024/1373659
Vancouver
Zuo S, He S, Zhu Z, Zhang Y, Hou Y, Wu Z, et al. Mitochondria‐Associated Gene SLC25A32 as a Novel Prognostic and Immunotherapy Biomarker: From Pan‐Cancer Multiomics Analysis to Breast Cancer Validation. Analytical Cellular Pathology. 2024. doi:10.1155/2024/1373659
BibTeX
@article{Zuo2024,
author = {Zuo, Shiqi and He, Siyuan and Zhu, Zhiqin and Zhang, Yingying and Hou, Yanjie and Wu, Ziqing and Tang, Yao},
title = {Mitochondria‐Associated Gene SLC25A32 as a Novel Prognostic and Immunotherapy Biomarker: From Pan‐Cancer Multiomics Analysis to Breast Cancer Validation},
journal = {Analytical Cellular Pathology},
year = {2024},
doi = {10.1155/2024/1373659}
}
EUVIMED